PBOA Praises Enactment of FDARA
2017-08-22
August 18, 2017 – Ringwood, NJ – The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, is pleased that H.R. 2430, the FDA Reauthorization Act (FDARA), has been signed into law, renewing four major user fee agreements between industry and FDA for FY2018 to FY2022.
PBOA president Gil Roth issued the following statement:
“A year ago, industry ratified the second iteration of Generic Drug User Fee Amendments (GDUFA II), and today I commend the White House for signing it into law via FDARA. GDUFA II will empower ... FOR MORE FOLLOW THIS LINK: http://www.pharma-bio.org/news/pboa-praises-enactment-of-fdara/
Groupe PARIMA Joins PBOA
2016-08-18
Pharma & Biopharma Outsourcing Association (PBOA), the trade association for CMOs and CDMOs, as a General Member. Read the news release.
Groupe PARIMA Appoints Vice-President, Product Development
2016-05-11
Groupe PARIMA is pleased to announce the appointment of Alain Desjardins, PhD as VP of Product Development.
“Dr. Desjardins brings considerable experience in product development and process validation, as well as a breath of scientific expertise, which includes not only semi-solid and liquid drug products, but also solid and sterile dosage forms,” said, Dr. Cantin. “I am confident he will implement innovative development strategies that will enable us to fully leverage our extensive resources and long-standing expertise to further meet our clients’ evolving needs in the global market.” A pharmaceutical industry veteran, Alain most recently served as the Director of Project Management at Groupe PARIMA. During the 20 years prior to that, he held Product Development positions of increasing responsibilities at Pharmascience, Valeant and Sandoz. Alain holds a PhD degree in Chemistry from McGill University in Montreal. This appointment is a further commitment from Groupe PARIMA to expand its presence in Product Development for global markets. “As a world class CDMO provider, Groupe Parima is already is uniquely positioned to help its clients seize opportunities all over the world. Alain’s wealth of knowledge and expertise will enhance our already strong development position.”
Since 2013, Groupe PARIMA’s contract Product Development segment business has experienced exceptionally strong growth driven by both small biotech companies as well as large pharma customers. Our clients, located all around the world, seek Groupe PARIMA’s expertise in the development of topical products. To support this significant increase in Product Development demand, Groupe PARIMA has invested heavily in the acquisition of new laboratory and scale-up equipment and tripled the Product Development headcount by hiring chemists, engineers and projects managers.
Groupe Parima will be at DCAT Week 2016
2016-03-07
Groupe Parima will be participating in DCAT week (New York City, March 14-17th), one largest gatherings in the world for pharmaceutical and related industries. To schedule a meeting with us at DCAT, please click on the following link (Meet at DCAT). We look forward to meeting you!
Come and Meet Us at CPhI Worldwide in Madrid
2015-09-28
Please come and meet us at CPhI Worldwide 2015 at the IFEMA - Feria de Madrid on October 13th to 15th. We will be available for meetings at your convenience during the event. To set up an appointment, use the following link (CPhI 2015) or contact us at bd@groupeparima.com. We look forward to meeting you.
Come and Meet Us at Contract Pharma 2015
2015-08-23
Please come and meet us at Contract Pharma 2015 Contracting and Outsourcing Conference and Tabletop Exhibition event at the Hyatt Regency in New Brunswick, NJ on September 17th and 18th. We will be at booth # 78 on September 17th and available for meetings at your convenience in NY/NJ during that entire week. To set up an appointment, use the following link (Contract Pharma 2015). We look forward to meeting you!
Groupe PARIMA Appoints President
2015-07-31
Groupe PARIMA announces today the appointment of Louis-David Cantin as President of the company. Since joining Groupe PARIMA in 2013, Mr. Cantin has been instrumental in leading the triple-digit growth of the Product Development business. In his new role, he will bring his 15 years of pharmaceutical R&D and business management experience to complete the transformation of Groupe PARIMA into a word class integrated pharmaceutical development and manufacturing organization.
Claude Mongrain, founder of Groupe PARIMA, will remain as CEO of the company. Mr. Mongrain will focus his activities on conducting business development throughout the world, establishing strategic partnerships and evaluating various growth opportunities.
Groupe PARIMA is a Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of pharmaceutical products as liquids, suspensions, semi-solids and sprays. With licenses from Health Canada and the US-FDA, Groupe PARIMA manufactures and ships products to all five continents. Groupe PARIMA clients range from small startup and virtual companies to global pharmaceutical companies located outside Canada.
Meet with us at 2015 BIO International Convention
2015-06-01
Groupe Parima will be participating in 2015 BIO International Convention (Philadelphia, June 15-18th), one largest gatherings in the world for biotechnology. To schedule a meeting with us at BIO, please click on the following link (Meet at BIO 2015) or use the BIO partnering platform. We look forward to seeing you!
